Strength Training and Testosterone Treatment Have Opposing Effects on Migration Inhibitor Factor Levels in Ageing Men
Table 2
Clinical and biochemical characteristics in patients during testosterone, placebo, and strength training.
Placebo
TT
ST ST + placebo
ST ST + TT
MIF (pg/mL)
(3–0)
203 (128–378)
182 (117–453)
266 (118–660)
253 (228–394)
(6–3)
205 (136–411)
282 (183–582)
207 (119–704)
277 (239–376)
(6–0)*
227 (141–649)
412 (170–777)
129 (101–471)
235 (169–301)
MCP-1 (pg/mL)
(3–0)
71 (59–85)
72 (63–105)
98 (62–109)
85 (59–87)
(6–3)*
74 (56–101)
84 (67–107)#
93 (70–117)#
76 (58–93)
(6–0)
82 (62–101)
80 (64–100)
72 (58–93)
79 (59–105)
MIP-1α (pg/mL)
(3–0)
27 (13–1981)
17 (8–1257)
13 (8–827)
200 (18–2884)
(6–3)
26 (13–1855)
17 (11–1318)
14 (9–798)
263 (18–2390)
(6–0)
31 (13–1800)
16 (10–1059)
13 (8–856)
347 (18–2152)
BioT (nmol/L)
(3–0)*
4.4 (3.3–6.0)
5.1 (4.3–6.1)##
5.1 (5.0–6.2)
5.7 (4.8–6.2)##§§
(6–3)
4.3 (3.3–4.8)
8.1 (5.6–12.3)
4.5 (4.2–5.0)
4.5 (4.1–5.1)
(6–0)**
3.9 (3.4–4.8)
9.7 (6.5–13.8)#
4.3 (3.7–4.4)
12.8 (7.3–16.3)##§
LBM (kg)
(3–0)**
64.7 (58.5–73.2)
64.7 (57.2–71.2)#
63.2 (59.8–68.7)
70.9 (65.1–78.2)##§
(6–3)
65.2 (58.9–73.3)
66.1 (59.9–72.2)
63.2 (57.5–68.9)
73.1 (63.3–78.2)
(6–0)*
64.3 (58.8–74.7)
65.8 (59.3–72.6)#
63.8 (5.9–6.9)
75.4 (66.0–78.7)#
Fat mass (kg)
(3–0)
23.9 (18.2–33.1)
24.4 (21.4–31.8)
25.0 (20.9–28.9)
25.4 (24.0–27.1)
(6–3)
24.3 (18.0–32.1)
23.8 (21.4–31.3)
25.9 (21.5–28.0)
25.9 (22.9–26.3)
(6–0)*
25.1 (19.2–31.3)
23.0 (20.3–30.2)#
24.2 (21.5–27.8)#
24.7 (21.5–25.9)#
CFM (kg)
(3–0)
13.1 (9.0–18.4)
14.0 (12.5–18.2)
13.9 (11.8–17.6)
15.0 (13.7–16.9)
(6–3)
13.1 (8.5–18.4)
13.6 (12.2–18.2)
14.5 (12.2–16.5)
14.6 (13.6–15.7)
(6–0)*
13.5 (9.2–17.6)
13.9 (11.2–17.4)#
12.4 (12.1–15.6)
13.5 (13.1–15.9)#
LEfat (kg)
(3–0)
6.9 (5.6–9.5)
6.5 (5.6–7.9)
7.2 (5.7–8.6)
7.4 (6.4–8.1)
(6–3)
7.2 (5.3–9.8)
6.4 (5.5–8.2)
7.2 (5.7–8.4)
6.8 (6.6–7.5)
(6–0)*
7.2 (5.8–9.7)
6.1 (5.2–8.0)#
6.8 (5.3–8.2)#
6.6 (6.5–7.2)#
SAT
(3–0)
24.2 (21.5–34.9)
29.2 (24.5–40.7)
29.6 (24.9–39.7)
27.9 (23.2–28.3)
(6–3)*
23.7 (20.8–35.3)
29.7 (24.2–40.1)##
30.3 (25.2–39.9)#
26.7 (23.4–28.7)
(6–0)**
25.7 (20.2–36.5)
25.6 (21.7–37.2)#
29.7 (24.0–37.4)#
26.6 (23.5–31.1)
Data presented as median (interquartile range). Kruskall-Wallis tests followed by Mann-Whitney test performed on delta values.
*
between groups, ** between groups (delta values).
# versus placebo, ## versus placebo. versus testosterone. versus training + placebo. ST: strength training. TT: testosterone treatment. LBM: lean body mass. SAT: subcutaneous adipose tissue. Visceral adipose tissue was unchanged during all interventions, and these results are omitted from the table.
